Abstract 4367443: Who Can Safely Stop Anticoagulation Following Left Ventricular Thrombus Resolution

H Hossam Elbenawi (Mayo Clinic, Rochester, Minnesota, United States) K Kirsten Lipps (Mayo Clinic, Rochester, Minnesota, United States) S Samuel Heller jr. (Second Faculty of Medicine, Charles University, Prague, Prague, Czechia) R Robert McBane (MAYO CLINIC, Rochester, Minnesota, United States) W Waldemar Wysokinski (Mayo Clinic, Rochester, Minnesota, United States) A Ana Casanegra (Mayo Clinic, Rochester, Minnesota, United States) S Stanislav Henkin T Thom Rooke (Mayo Clinic, Rochester, Minnesota, United States) P Paul Wennberg (Mayo Clinic, Rochester, Minnesota, United States) D David Liedl (Mayo Clinic, Rochester, Minnesota, United States) R Raymond C Shields (Mayo Clinic, Rochester, Minnesota, United States) D Damon Houghton (Mayo Clinic, Rochester, Minnesota, United States)

Abstract

Background: Whether oral anticoagulation (OAC) can be discontinued after the resolution of left ventricular thrombus (LVT) remains controversial, particularly in patients without risk factors such as left ventricular aneurysms. This study aimed to identify patients who may safely discontinue OAC. Methods: We conducted a retrospective cohort study of patients with LVT resolution who completed their anticoagulation course and excluded patients with left ventricular (LV) aneurysm. Clinical and echocardiographic factors were compared between patients who experienced LVT recurrence (n = 22) and those without recurrence during follow-up (n = 94). Results: The cohort had a mean age of 64.5 ± 15.0 years, and half (50%) were male. Most had an ischemic cardiomyopathy (64.6%). LVT recurred in 19% (22/116) of patients following initial resolution. Patients with recurrence were older (mean age 71.3 ± 11.9 vs. 63.4 ± 15.7 years, p = 0.03) and were more likely to have prior ischemic stroke and arterial thromboembolism (18.2% vs. 4.3%, p = 0.02 for both). At the time of thrombus resolution, LVEF was significantly lower among patients who had recurrence (33.4 ± 13.6% vs. 42.5 ± 15.5%, p = 0.012). Stroke, systemic embolism, and mortality rates were similar regardless of recurrence status. Recurrence risk by presence or absence of stroke and LEVF >50% on the LVT resolution echocardiogram is shown in Figure 1. Notably, no recurrences were observed among patients with both LVEF > 50% and no history of stroke (0/32), which was statistically significant compared to each other category. Conclusion: Among patients without left ventricular aneurysm who discontinued oral anticoagulation after LVT resolution, those with preserved LVEF (>50%) and no prior history of stroke had a very low risk of recurrence, with no events observed in this subgroup. These findings suggest that some patients may safely discontinue anticoagulation after LVT resolution.

Article Details

Journal Circulation
Volume / Issue Vol. 152, Issue Suppl_3
Published November 04, 2025
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (12)

H

Hossam Elbenawi

Mayo Clinic, Rochester, Minnesota, United States

K

Kirsten Lipps

Mayo Clinic, Rochester, Minnesota, United States

S

Samuel Heller jr.

Second Faculty of Medicine, Charles University, Prague, Prague, Czechia

R

Robert McBane

MAYO CLINIC, Rochester, Minnesota, United States

W

Waldemar Wysokinski

Mayo Clinic, Rochester, Minnesota, United States

A

Ana Casanegra

Mayo Clinic, Rochester, Minnesota, United States

S

Stanislav Henkin

T

Thom Rooke

Mayo Clinic, Rochester, Minnesota, United States

P

Paul Wennberg

Mayo Clinic, Rochester, Minnesota, United States

D

David Liedl

Mayo Clinic, Rochester, Minnesota, United States

R

Raymond C Shields

Mayo Clinic, Rochester, Minnesota, United States

D

Damon Houghton

Mayo Clinic, Rochester, Minnesota, United States